LivaNova (LIVN) Stock Price, News & Analysis

Company Overview

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve. The company also develops related programming and patient-management technologies.

Through its Cardiopulmonary business, LivaNova provides products used in cardiac surgery and other procedures requiring extracorporeal circulation. Its portfolio includes heart-lung machines, oxygenators, perfusion systems and other cardiopulmonary support products, including the Essenz Heart-Lung Machine System. LivaNova was created in 2015 through the merger of Cyberonics, a neuromodulation company, and Sorin, a cardiovascular device company. The company is headquartered in London, and Vladimir Makatsaria has served as its chief executive officer since 2022.

Key Stats

• Today's Range: $76.78 to $77.85
• 50-Day Range: $75.78 to $85.32
• 52-Week Range: $48.82 to $85.76
• Volume: 98,694 shs
• Average Volume: 745,307 shs
• Market Capitalization: $4.27 billion
• P/E Ratio: 22.93
• Dividend Yield: N/A
• Price Target: $84.13
• Consensus Rating: Moderate Buy

LivaNova Stock Analysis - MarketRank™

LivaNova scored higher than 54% of companies evaluated by MarketBeat, and ranked 495th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LivaNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on no strong buy ratings, 6 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for LivaNova is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

LivaNova has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.81%

Earnings Growth

Earnings for LivaNova are expected to grow by 9.81% in the coming year, from $3.77 to $4.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LivaNova is 23.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of LivaNova is 23.01, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.33.

Price to Book Value per Share Ratio

LivaNova has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.09% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 8.96.

Change versus previous month

Short interest in LivaNova has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LivaNova does not currently pay a dividend.

Dividend Growth

LivaNova does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.71

News Sentiment

LivaNova has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for LivaNova this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LivaNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $591,839.00 in company stock.

Percentage Held by Insiders

0.35% of the stock of LivaNova is held by insiders.

Percentage Held by Institutions

97.64% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/18/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:LIVN
• CIK: 1639691
• Web: www.livanova.com
• Phone: 442033250660
• Fax: 281-218-9332
• Employees: 3,300
• Year Founded: 2015

Price Target and Rating

• Average Price Target for LivaNova: $84.13
• High Price Target: $95.00
• Low Price Target: $66.00
• Potential Upside/Downside: +9.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.55
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.38
• Trailing P/E Ratio: 22.77
• Forward P/E Ratio: 20.39
• P/E Growth: N/A
• Net Income: -$242.47 million
• Net Margins: 12.82%
• Pretax Margin: 7.31%
• Return on Equity: 16.35%
• Return on Assets: 7.76%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 1.45
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $1.47 billion
• Price / Sales: 2.88
• Cash Flow: $4.74 per share
• Price / Cash Flow: 16.23
• Book Value: $21.98 per share
• Price / Book: 3.50

Miscellaneous

• Outstanding Shares: 55,094,000
• Free Float: 54,901,000
• Market Cap: $4.23 billion
• Optionable: Optionable
• Beta: 0.87